Next-Generation Estrogen Receptor–Targeted Therapeutics

IF 4.7 2区医学 Q1 ONCOLOGY

Annual Review of Cancer Biology-Series Pub Date : 2023-01-25 DOI:10.1146/annurev-cancerbio-061421-013525

T. Fernando, H. Moore, M. Wongchenko, Ciara Metcalfe

{"title":"Next-Generation Estrogen Receptor–Targeted Therapeutics","authors":"T. Fernando, H. Moore, M. Wongchenko, Ciara Metcalfe","doi":"10.1146/annurev-cancerbio-061421-013525","DOIUrl":null,"url":null,"abstract":"Estrogen receptor (ER) α is expressed in the vast majority of breast cancers and is one of the most successfully prosecuted drug targets in oncology, with multiple classes of endocrine therapies approved for the treatment of ER+ breast cancer. These existing agents are highly active, both as single agents and as combination partners for other targeted therapies, and have significantly benefited patients. However, each of these standard-of-care (SOC) therapies has liabilities that allow for the reengagement of ER signaling as a mechanism of resistance. Data supporting the continued dependence of tumors on ER signaling following exposure to SOC agents have underpinned an extraordinary reenergizing of academic, biotechnology, and pharmaceutical groups pursuing next-generation ER-targeted therapies. The hypothesis that there remains an opportunity to bring further meaningful benefit to patients through fully optimized ER-targeted therapies is currently being investigated in the clinic. Expected final online publication date for the Annual Review of Cancer Biology, Volume 7 is April 2023. Please see http://www.annualreviews.org/page/journal/pubdates for revised estimates.","PeriodicalId":54233,"journal":{"name":"Annual Review of Cancer Biology-Series","volume":" ","pages":""},"PeriodicalIF":4.7000,"publicationDate":"2023-01-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annual Review of Cancer Biology-Series","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1146/annurev-cancerbio-061421-013525","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 2

Abstract

Estrogen receptor (ER) α is expressed in the vast majority of breast cancers and is one of the most successfully prosecuted drug targets in oncology, with multiple classes of endocrine therapies approved for the treatment of ER+ breast cancer. These existing agents are highly active, both as single agents and as combination partners for other targeted therapies, and have significantly benefited patients. However, each of these standard-of-care (SOC) therapies has liabilities that allow for the reengagement of ER signaling as a mechanism of resistance. Data supporting the continued dependence of tumors on ER signaling following exposure to SOC agents have underpinned an extraordinary reenergizing of academic, biotechnology, and pharmaceutical groups pursuing next-generation ER-targeted therapies. The hypothesis that there remains an opportunity to bring further meaningful benefit to patients through fully optimized ER-targeted therapies is currently being investigated in the clinic. Expected final online publication date for the Annual Review of Cancer Biology, Volume 7 is April 2023. Please see http://www.annualreviews.org/page/journal/pubdates for revised estimates.

查看原文本刊更多论文

下一代雌激素受体-靶向治疗

雌激素受体（ER）α在绝大多数乳腺癌中表达，是肿瘤学中最成功的药物靶点之一，多种内分泌疗法已被批准用于治疗ER+乳腺癌症。这些现有的药物具有高度活性，无论是作为单一药物还是作为其他靶向治疗的联合伙伴，都使患者受益匪浅。然而，这些标准护理（SOC）疗法中的每一种都有责任将ER信号作为一种耐药性机制重新参与。支持肿瘤在暴露于SOC制剂后对ER信号持续依赖的数据支持了学术、生物技术和制药团体追求下一代ER靶向疗法的非凡复兴。目前，临床上正在研究通过完全优化的ER靶向治疗为患者带来进一步有意义的益处的假设。《癌症生物学年度评论》第7卷预计最终在线出版日期为2023年4月。请参阅http://www.annualreviews.org/page/journal/pubdates用于修订估算。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Annual Review of Cancer Biology-Series Medicine-Oncology

CiteScore

14.50

自引率

1.30%

发文量

期刊介绍： The Annual Review of Cancer Biology offers comprehensive reviews on various topics within cancer research, covering pivotal and emerging areas in the field. As our understanding of cancer's fundamental mechanisms deepens and more findings transition into targeted clinical treatments, the journal is structured around three main themes: Cancer Cell Biology, Tumorigenesis and Cancer Progression, and Translational Cancer Science. The current volume of this journal has transitioned from gated to open access through Annual Reviews' Subscribe to Open program, ensuring all articles are published under a CC BY license.